Exercise as a platform for pharmacotherapy development in cardiac diseases

Area of Science:

• Cardiovascular Research
• Exercise Physiology
• Molecular Cardiology

Background:

• Cardiovascular diseases (CVDs) pose a significant global health burden.
• Pathological cardiac growth leads to dysfunction, fibrosis, and cell death.
• Moderate exercise offers a cost-effective preventive and therapeutic strategy for CVDs.

Purpose of the Study:

• To elucidate the mechanisms of exercise-induced physiological cardiac growth.
• To explore exercise's role in cardiac regeneration and aging.
• To identify novel therapeutic targets for cardiac diseases based on exercise pathways.

Main Methods:

• Review of current literature on exercise and cardiac adaptation.
• Analysis of signaling pathways involved in exercise-induced cardiomyogenesis and angiogenesis.
• Investigation of exercise's impact on cardiac aging and metabolism.
• Examination of microRNA regulation in response to exercise.

Main Results:

• Exercise induces balanced cardiomyogenesis (hypertrophy and hyperplasia) and neo-angiogenesis without cell death or fibrosis.
• Key signaling pathways like IGF-1-PI3K-Akt, nitric oxide (NO), C/EBPβ, and PGC-1α mediate exercise-induced cardiac growth.
• Exercise enhances cardiac regenerative capacity and protects against aging and metabolic dysfunction.
• Exercise modulates cardiac and circulating microRNAs.

Conclusions:

• Moderate exercise promotes beneficial cardiac remodeling and cardioprotection through specific molecular pathways.
• Understanding these mechanisms can inform the development of new pharmacotherapies for heart conditions.
• Exercise represents a powerful, non-pharmacological intervention for cardiovascular health and disease management.